文献速递糖尿病肥胖与代谢综合征

GLP-1受体激动剂与DPP-4抑制剂治疗糖尿病患者主要心血管及肢体不良事件比较

Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors.
PubMed 文献 · Diabetologia · 2021-06-30

基于台湾全民健康保险数据库的回顾性队列研究,经倾向评分匹配后比较GLP-1受体激动剂(GLP1RA)与DPP-4抑制剂(DPP4i)治疗2型糖尿病患者的结局。GLP1RA组主要不良肢体事件复合终点发生率显著低于DPP4i组(2.59 vs 4.22事件/1000人年;SHR 0.63,95%CI 0.41-0.96),主要归因于截肢率降低(1.29 vs 2.4事件/1000人年;SHR 0.55,95%CI 0.30-0.99)。GLP1RA组次要心血管复合终点风险亦显著降低(11.02 vs 17.95事件/1000人年;HR 0.62,95%CI 0.51-0.76)。

要点

  • GLP1RA较DPP4i显著降低主要不良肢体事件复合终点风险(SHR 0.63)。
  • 截肢率降低是主要驱动因素(SHR 0.55)。
  • GLP1RA还降低心血管死亡、非致死性心梗和非致死性卒中复合风险(HR 0.62)。

核心结论

  • 在糖尿病患者中,使用GLP1RA与主要不良肢体事件风险显著低于使用DPP4i相关。
  • 风险降低主要由截肢率下降驱动。
  • GLP1RA治疗还与心血管死亡、非致死性卒中、非致死性心肌梗死及全因死亡风险降低相关。

研究设计与样本

  • 共识别1,080,993例接受GLP1RA或DPP4i治疗的2型糖尿病患者。
  • 经1:3倾向评分匹配后,GLP1RA组4,460例,DPP4i组13,380例。

主要发现

  • 主要复合终点(外周动脉疾病、临界肢体缺血、经皮腔内血管成形术或外周旁路术、截肢)发生率:GLP1RA组2.59 vs DPP4i组4.22事件/1000人年;SHR 0.63(95%CI 0.41, 0.96)。
  • 截肢发生率:GLP1RA组1.29 vs DPP4i组2.4事件/1000人年;SHR 0.55(95%CI 0.30, 0.99)。
  • 次要心血管复合终点(心血管死亡、非致死性心肌梗死、非致死性缺血性卒中)发生率:GLP1RA组11.02 vs DPP4i组17.95事件/1000人年;HR 0.62(95%CI 0.51, 0.76)。
  • GLP1RA对复合肢体不良结局的有利效应在非心血管患者和他汀使用者中尤为明显(交互作用P<0.05)。

临床怎么用

  • 对于2型糖尿病患者,尤其关注肢体不良事件风险者,GLP1RA相较DPP4i可能带来额外肢体保护获益。
  • 在非心血管疾病患者和他汀使用者中,GLP1RA的肢体获益可能更明显。

局限性

  • 观察性研究可能存在未探索的混杂因素。
  • 需要未来大规模随机对照试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP1RAs) and dipeptidyl peptidase-4 inhibitors (DPP4is) in major cardiovascular adverse events were previously examined in cardiovascular outcome trials. However, the effects of these drugs on adverse limb outcomes were poorly examined. This study aimed to determine the real-world outcomes of patients with diabetes mellitus receiving GLP1RAs as compared with those receiving DPP4is in terms of major adverse cardiovascular and limb events. METHODS: A retrospective cohort study was conducted with data collected by the Taiwan National Health Insurance database between 1 May 2011 and 31 December 2017. Patients who were treated for type 2 diabetes with a GLP1RA or DDP4i during this period (n = 1,080,993), were identified. The primary outcome was a composite of major adverse limb events, defined as peripheral artery disease (PAD), critical limb ischaemia, percutaneous transluminal angioplasty or peripheral bypass for PAD, and amputation. The secondary cardiovascular outcome was the composite of cardiovascular death, non-fatal myocardial infarction and non-fatal ischaemic stroke. Propensity-score matching (PSM) at a 1:3 ratio between GLP1RA and DPP4i groups was done to minimise possible selection bias. RESULTS: A total of 948,342 individuals treated between 1 May 2011 and 31 December 2017, were identified, with 4460 in the GLP1RA group and 13,380 in the DPP4i group after PSM. The incidence of primary composite outcome events was significantly lower in those treated with GLP1RAs compared with those treated with DPP4is (2.59 vs 4.22 events per 1000 person-years; subdistribution HR [SHR] 0.63 [95% CI 0.41, 0.96]), primarily due to lower rates of amputation (1.29 events per 1000 person-years for GLP1RAs vs 2.4 events per 1000 person-years for DPP4is; SHR 0.55 [95% CI 0.30, 0.99]). Treatment with GLP1RAs was also associated with significantly lower risks of secondary composite outcome events (11.02 vs 17.95 events per 1000 person-years; HR 0.62 [95% CI 0.51, 0.76]). Moreover, the observed beneficial effects of GLP1RAs on reducing composite adverse limb outcomes were particularly noticeable in the non-cardiovascular patients and statin users (p for interaction <0.05). CONCLUSIONS/INTERPRETATION: In individuals with diabetes, the use of GLP1RAs was associated with significantly lower risks of major adverse limb events when compared with the use of DPP4is. The reduction in risk was driven largely by reduced rate of amputations. Moreover, treatment with GLP1RAs was also associated with lower risks of cardiovascular death, non-fatal stroke, non-fatal myocardial infarction and death from any cause. However, some unexplored confounding factors may exist in this observation study and future large-scale randomised controlled trials are needed.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Lin DS, Lee JK, Chen WJ, et al. Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors. Diabetologia. 2021. PMID: 34195865. doi:10.1007/s00125-021-05497-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。